Parabilis Medicines Reports Q3 2026 Results, Holds $1.1 Billion in Cash
Parabilis Medicines reported Q3 2026 revenue of $2.1M and a net loss of $44.5M, with $1.1B in cash. R&D expenses rose to $45.6M. The company presented clinical progress for zolucatetide, including a 72.2% response rate in desmoid tumors. It plans a Phase 3 trial in 2027 and collaborations with Revolution Medicines.
How this was made

The 30-second read
Why it matters
The earnings release highlights a significant net loss and cash burn, but also promising early trial data and FDA alignment for a pivotal Phase 3 study, creating a mixed short‑term/long‑term outlook.
Market read
Primary micro‑cap earnings release with new trial data; short‑term downside risk due to loss, but long‑term upside potential from trial progress.
What to watch
The $1.1B cash runway through 2030 provides ample funding for upcoming trials, reducing near‑term financing risk.
Background
Parabilis Medicines (PBLS) filed an 8‑K with Q3 2026 financials and disclosed clinical progress for its lead candidate zolucatetide.
Ticker impact
Parabilis Medicines reported Q3 2026 results with $2.1M revenue, $44.5M net loss and $1.1B cash, plus Phase 1/2 desmoid tumor data and FDA alignment for a Phase 3 trial.
likely pressure as the market prices in the sizable net loss and cash burn
The disclosed loss and cash burn are material for a micro‑cap biotech, outweighing the positive trial readout which is still early‑stage.
Market effects
Biotech sector may see modest interest in Wnt/β‑catenin pathway programs.
Limited to US‑listed biotech investors.
Low; impact confined to niche biotech investors.
Counterpoint
The strong desmoid tumor response could outweigh short‑term loss concerns, prompting a buy on long‑term potential.
Key entities
- companyParabilis Medicines
Biotech firm developing zolucatetide for Wnt/β‑catenin‑driven tumors.
- companyRevolution Medicines
Partner in a clinical collaboration on zolucatetide.
